What Is CJC-1295?

Teichman et al. (J. Clin. Endocrinol. Metab.): Single injection increases GH 2-10x for 6+ days and IGF-1 1.5-3x for 9-11 days in healthy adults. Well-tolerated at 30-60 µg/kg.

Ionescu & Bhatt (J. Clin. Endocrinol. Metab.): Demonstrates 7.5-fold increase in basal GH, 46% increase in mean GH, and 45% increase in IGF-1 while preserving natural pulsatile pattern.

Animal study shows CJC-1295 increases total pituitary RNA and GH mRNA, suggesting proliferation of somatotroph cells for sustained GH production.

Therapeutic peptides offer mechanistically diverse approaches to targeting fundamental hallmarks of aging, a 2026 review demonstrated. While FDA-approved agents show clinical potential, investigational peptides require rigorous validation through well-designed trials to establish long-term safety and efficacy.

A 2026 review found that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, though rigorous human safety data remain scarce. The study investigated the pharmacological mechanisms and regulatory status of various sports medicine peptides.

Limited clinical evidence supports the use of performance-enhancing peptides in sports despite their growing popularity, a 2026 review found. The research highlighted significant potential risks, including cardiovascular strain and insulin resistance, alongside major challenges in regulation and anti-doping detection.

Therapeutic peptides such as BPC-157 and TB-500 were found to modulate key molecular pathways influencing tissue regeneration and inflammation resolution in a 2026 review. The study demonstrated that while preclinical mechanistic data is promising for orthopaedic applications, clinical trials remain lacking.

A 2026 review found a significant lack of human clinical evidence to support the use of peptides like BPC-157 and TB-4 in orthopaedics, despite demonstrating potential tissue repair benefits in preclinical models.

A 2026 study demonstrated the successful development and validation of a highly sensitive mass spectrometry method for detecting growth hormone-releasing hormone (GHRH) and its analogs, including sermorelin, tesamorelin, and CJC-1295, in urine. The method achieved limits of detection suitable for anti-doping screening.

A 2024 study demonstrated the successful development and validation of a simplified chromatographic-mass spectrometric method for detecting prohibited peptides, including insulins, GHRHs, and IGFs, in doping control urine samples. The approach met World Anti-Doping Agency standards and was verified using authentic post-administration samples.

A 2023 study demonstrated a newly validated UHPLC-MS/MS method capable of detecting growth hormone-releasing hormones like tesamorelin and CJC-1295 in urine at concentrations as low as 0.2 ng/mL. This provides a highly sensitive and reliable technique for routine anti-doping screening.

A 2022 study demonstrated that a generic solid-phase extraction and high-resolution mass spectrometry method successfully detected various banned peptides, including insulins, GHRHs, and IGFs, in blood samples. The method met World Anti-Doping Agency criteria and was validated using post-administration samples.

A 2022 study demonstrated an antibody-free, ultrafiltration-based assay capable of detecting growth hormone-releasing hormone analogues, including sermorelin and CJC-1295, in urine at low concentrations. Researchers found this method provided high sensitivity and enhanced recovery rates compared to traditional purification techniques.

A 2022 study demonstrated that cannabidiol and carboxy-THC act as extracellular ligands for the growth hormone secretagogue receptor (GHS-R1a). Researchers found these cannabinoids strongly promote the binding of ghrelin, enabling their early detection in biological samples without interference from synthetic ghrelin mimetics.

A 2021 in vitro study demonstrated a new, sensitive detection method for four growth hormone-releasing hormone (GHRH) synthetic analogs in urine. Researchers identified 19 metabolites for peptides like sermorelin and CJC-1295, achieving detection limits of 1 ng/ml or less to enhance anti-doping screening.

A 2020 study demonstrated an optimized immunopurification method using magnetic beads and mass spectrometry to detect growth hormone-releasing hormone and its analogues in human urine. The validated technique successfully identified target peptides like sermorelin and CJC-1295 with a detection limit of 0.2 ng/mL.

A 2019 study demonstrated a novel LC-MS/MS method capable of confirming CJC-1295 in equine plasma following immuno-affinity capture and tryptic digestion. Researchers found this technique successfully identified the peptide at concentrations as low as 180 pg/mL.

A 2019 study demonstrated that an immuno-polymerase chain reaction assay successfully detected CJC-1295-protein conjugates in equine plasma at concentrations as low as 0.8 pg/mL. The assay's effectiveness was confirmed in thoroughbred racehorses, providing a method to monitor illicit peptide use.

A 2016 analysis of internet forums found that peptides like CJC-1295 are emerging as popular new products in the online doping market. The study demonstrated that semantic analysis of online communities can successfully track these market trends and identify substance suppliers.

A 2016 study demonstrated that a novel immunoaffinity-mass spectrometry method successfully detected four growth hormone-releasing hormones, including Sermorelin, CJC-1295, and Tesamorelin, in human plasma. The validated approach also identified specific metabolites, providing a reliable tool for sports anti-doping tests.